Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May 30;35(12):1972-84.
doi: 10.1002/sim.6848. Epub 2015 Dec 23.

Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels

Affiliations

Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels

Magdalena Żebrowska et al. Stat Med. .

Abstract

Consider a parallel group trial for the comparison of an experimental treatment to a control, where the second-stage sample size may depend on the blinded primary endpoint data as well as on additional blinded data from a secondary endpoint. For the setting of normally distributed endpoints, we demonstrate that this may lead to an inflation of the type I error rate if the null hypothesis holds for the primary but not the secondary endpoint. We derive upper bounds for the inflation of the type I error rate, both for trials that employ random allocation and for those that use block randomization. We illustrate the worst-case sample size reassessment rule in a case study. For both randomization strategies, the maximum type I error rate increases with the effect size in the secondary endpoint and the correlation between endpoints. The maximum inflation increases with smaller block sizes if information on the block size is used in the reassessment rule. Based on our findings, we do not question the well-established use of blinded sample size reassessment methods with nuisance parameter estimates computed from the blinded interim data of the primary endpoint. However, we demonstrate that the type I error rate control of these methods relies on the application of specific, binding, pre-planned and fully algorithmic sample size reassessment rules and does not extend to general or unplanned sample size adjustments based on blinded data. © 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd.

Keywords: adaptive clinical trials; blinded interim analysis; block randomization; random allocation; sample size reassessment; type I error rate control.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparing the asymptotic results with MCMC output for an example data set.
Figure 2
Figure 2
Maximum type I error rate as a function of the secondary endpoint effect size with and without restrictions for the second stage sample size. Here, the first stage sample size n 1=144 and σ = 1. (Black) solid lines denote unrestricted results, and (red) dashed lines results for restricted case with n2min=n1/2 and n2max=4n1. ρ∈{0,0.5,0.8,0.9,1} and the larger the ρ the thicker the line.
Figure 3
Figure 3
Maximum type I error rate without restrictions for the second stage sample size and for blocked randomization with block sizes 2, 4, 6 and the unblocked design (n 1=144,ρ = 0,σ = 1, and 2.5·105 (2·105) simulation runs for block size 2 (4, 6, unblocked design)).

Similar articles

Cited by

References

    1. ICH Topic E9: Notes for guidance on statistical principles for clinical trials, European Agency for the Evaluation of Medical Products: London, UK, 1998.
    1. Proschan MA, Hunsberger SA. Designed extension of studies based on conditional power. Biometrics. 1995; 51: 1315–1324. - PubMed
    1. Graf AC, Bauer P. Maximum inflation of the type 1 error rate when sample size and allocation rate are adapted in a pre‐planned interim look. Statistics in Medicine. 2011; 30: 1637–1647. - PMC - PubMed
    1. Bauer P, Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics. 1994; 50: 1029–1041. - PubMed
    1. Posch M, Bauer P, Brannath W. Issues in designing flexible trials. Statistics in Medicine. 2003; 23: 953–969. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources